EU Commission to restrict Chinese companies in medical devices procurement
.png)
The European Commission, the primary executive arm of the EU, announced their decision to exclude Chinese companies from EU government purchases of medical devices exceeding EUR€5 million in a bid to rebalance trade barriers.
The decision follows results from an initial investigation under the International Procurement Instrument (IPI), and will allow no more than 50% of inputs from China for successful procurement bids, though exclusions apply if no alternative suppliers are available. The IPI investigation and subsequent decision are in response to what the Commission deems proportionate to barriers in China, aiming to incentivise China to include EU-made medical devices in Chinese government contracts.
From 2015 to 2023, imports of Chinese medical devices to the EU more than doubled, while China has made it significantly more difficult for EU companies to export to their market – 87% of public procurement contracts for medical devices in China were subject to legislation the EU Commission claims are “exclusionary and discriminatory”. EU officials also claim Medtech Europe figures value the EU medical technology market at approximately EUR€150 billion in 2023, with public procurement making up 70%. With global public procurement valued at over EUR€11 trillion annually, the EU public procurement market states it is one of the most open markets globally. The EU Commission’s ban would cover medical devices such as imaging equipment, artificial body parts, and medical clothing. The Commission also stated that “clear evidence” showed China favouring Chinese devices for hospitals, and that its tender conditions continually resulted in low bids.
While dialogue between the two regions is still open, China’s commerce ministry has previously called the measures as “protectionist”, and urged for transparency on both sides to resolve the issues. Meanwhile, the EU Commission has stated that China has not proposed any concrete and satisfactory solutions, leading to the implementation of such measures.
Sources:
Commission restricts Chinese participation in medical devices procurement [Accessed June 23, 2025] https://ec.europa.eu/commission/presscorner/detail/en/ip_25_1569
EU bars Chinese firms from most medical device tenders [Accessed June 23, 2025] https://www.reuters.com./business/healthcare-pharmaceuticals/eu-bars-chinese-firms-most-medical-device-tenders-2025-06-20/
Related News
-
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News AstraZeneca invests in AI-led research agreement with China's CSPC, up to US$5.3 billion
Anglo-Swedish pharmaceutical giant AstraZeneca announced they have signed a deal with China’s CSPC Pharmaceutical Group worth up to US$5.3 billion to drive AI-led research development of therapies for chronic conditions.
-
News CPHI Americas 2025 - From the Floor
Our From the Floor live blog is back in Philadelphia for this year’s CPHI, this time under the new name CPHI Americas to embrace and represent the whole of the pharmaceutical supply chain from north to south.
-
News Women in Pharma: Unlocking patient inclusion at CPHI Americas
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can towards making the healthcare industry and workplace more equitable and inclusive.&nbs... -
News Tracking Innovation with Thermo Fisher Scientific: CPHI Americas Track Sponsor interview
As we gear up for CPHI Americas from May 20-22, 2025 at the Philadelphia Convention Center, we sat down with Track Sponsor Thermo Fisher Scientific to discuss the future of bioproduction in pharma.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Executive order to elevate US pharma manufacturing signed by Trump
On Monday, May 5, US President Trump signed an executive order to reduce regulatory barriers for domestic US pharmaceutical manufacturing, including key ingredients and materials for manufacturing prescription drugs.